Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Breast Cancer

Free Subscription 09.03.2020 1 Am J Surg 2 Ann Surg Oncol 5 Anticancer Res 4 BMC Cancer 1 BMJ 5 Breast Cancer 5 Breast Cancer Res Treat 4 Breast J 1 Cancer Cell 3 Cancer Epidemiol Biomarkers Prev 4 Clin Breast Cancer 1 Eur J Cancer 2 Eur J Surg Oncol 1 Int J Cancer 2 Int J Oncol 1 J Biol Chem 1 J Clin Invest 2 J Clin Oncol 1 J Natl Cancer Inst 2 J Pathol 2 Lancet 7 Lancet Oncol 1 Nat Rev Clin Oncol 2 NPJ Breast Cancer 2 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Surg

1. GOONAWARDENA J, Yong C, Law M
   Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis.
   Am J Surg. 2020 Feb 7. pii: S0002-9610(20)30069.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

2. SMITH ME, Vitous CA, Hughes TM, Shubeck SP, et al
   Barriers and Facilitators to De-Implementation of the Choosing Wisely((R)) Guidelines for Low-Value Breast Cancer Surgery.
   Ann Surg Oncol. 2020 Mar 2. pii: 10.1245/s10434-020-08285.
   PubMed     Text format     Abstract available
   
   
3. YAMAGISHI Y, Yamasaki T, Ishida J, Moriya T, et al
   Utility of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer.
   Ann Surg Oncol. 2020 Mar 2. pii: 10.1245/s10434-020-08269.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

4. HONG SE, Kim MR, Jang SK, Seong MK, et al
   Hypoxia Suppresses Cysteine Deprivation-induced Cell Death Via ATF4 Regulation in MDA-MB-231 Breast Cancer Cells.
   Anticancer Res. 2020;40:1387-1394.
   PubMed     Text format     Abstract available
   
   
5. GKRETSI V, Stylianou A, Kalli M, Louca M, et al
   Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes.
   Anticancer Res. 2020;40:1375-1385.
   PubMed     Text format     Abstract available
   
   
6. ALKHAYYAL N, Talaat I, Vinodnadat A, Maghazachi A, et al
   Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE.
   Anticancer Res. 2020;40:1555-1561.
   PubMed     Text format     Abstract available
   
   
7. CIPOLLA C, Graceffa G, Cabibi D, Gangi G, et al
   Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer.
   Anticancer Res. 2020;40:1711-1717.
   PubMed     Text format     Abstract available
   
   
8. ARKOSY P, Toth J, Beres E, Toth D, et al
   Prognosis and Treatment Outcomes of Patients Undergoing Resection of Brain Metastases from Breast Cancer.
   Anticancer Res. 2020;40:1759-1770.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. ZHANG XM, Dou QL, Zeng Y, Yang Y, et al
   Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review.
   BMC Cancer. 2020;20:172.
   PubMed     Text format     Abstract available
   
   
10. KHIL L, Heidrich J, Wellmann I, Kaab-Sanyal V, et al
    Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study.
    BMC Cancer. 2020;20:174.
    PubMed     Text format     Abstract available
    
    
11. GAO G, Wang Z, Qu X, Zhang Z, et al
    Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:179.
    PubMed     Text format     Abstract available
    
    
12. SUN Z, Lan X, Xu S, Li S, et al
    Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    BMC Cancer. 2020;20:180.
    PubMed     Text format     Abstract available
    
    

    
    BMJ

13. TORJESEN I
    Health groups criticise EU funded breast cancer screening study as a "missed opportunity".
    BMJ. 2020;368:m855.
    PubMed     Text format    
    
    

    
    Breast Cancer

14. YAMAMOTO S, Masutani E, Arao H
    Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy.
    Breast Cancer. 2020 Feb 29. pii: 10.1007/s12282-020-01062.
    PubMed     Text format     Abstract available
    
    
15. MANGONE L, Ferrari F, Mancuso P, Carrozzi G, et al
    Epidemiology and biological characteristics of male breast cancer in Italy.
    Breast Cancer. 2020 Feb 29. pii: 10.1007/s12282-020-01068.
    PubMed     Text format     Abstract available
    
    
16. OKUMURA S, Hyodo I, Iwata H, Kamei Y, et al
    Immediate one-stage implant-based breast reconstruction without the use of acellular dermal matrix in Japanese breast cancer patients.
    Breast Cancer. 2020 Mar 4. pii: 10.1007/s12282-020-01073.
    PubMed     Text format     Abstract available
    
    
17. GOTO Y, Tsugawa K, Furuya Y, Maezato M, et al
    Behavior of Japanese women after being informed about the benefits and disadvantages of breast cancer screening: a questionnaire survey.
    Breast Cancer. 2020 Mar 5. pii: 10.1007/s12282-020-01071.
    PubMed     Text format     Abstract available
    
    
18. MIYOSHI Y, Yoshimura Y, Saito K, Muramoto K, et al
    High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
    Breast Cancer. 2020 Mar 5. pii: 10.1007/s12282-020-01067.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

19. IWASE M, Ando M, Aogi K, Aruga T, et al
    Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Mar 5. pii: 10.1007/s10549-020-05580.
    PubMed     Text format     Abstract available
    
    
20. MASUDA T, Fujimoto H, Teranaka R, Kuroda M, et al
    Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05581.
    PubMed     Text format     Abstract available
    
    
21. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05567.
    PubMed     Text format     Abstract available
    
    
22. TAYLOR LJ, Steiman JS, Anderson B, Schumacher JR, et al
    Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?
    Breast Cancer Res Treat. 2020 Mar 3. pii: 10.1007/s10549-020-05579.
    PubMed     Text format     Abstract available
    
    
23. ANDREANO KJ, Wardell SE, Baker JG, Desautels TK, et al
    G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 4. pii: 10.1007/s10549-020-05575.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

24. GUO LN, Gawelek KL, Russell-Goldman E, Nambudiri VE, et al
    Seeding from percutaneous liver biopsy: A case of iatrogenic cutaneous breast cancer.
    Breast J. 2020 Mar 5. doi: 10.1111/tbj.13794.
    PubMed     Text format    
    
    
25. RODRIGUEZ PALLEIRO MC, Krygier Waltier G
    The impact of 21-Gene Recurrence Score test and classic clinical-pathologic factors in guiding adjuvant therapy for HER-2 negative, ER-positive, early-stage breast cancer: A retrospective study.
    Breast J. 2020 Mar 3. doi: 10.1111/tbj.13787.
    PubMed     Text format    
    
    
26. KHALLAF E, Wessam R, Abdoon M
    Targeted axillary dissection of carbon-tattooed metastatic lymph nodes in combination with post-neo-adjuvant sentinel lymph node biopsy using 1% methylene blue in breast cancer patients.
    Breast J. 2020 Mar 2. doi: 10.1111/tbj.13736.
    PubMed     Text format    
    
    
27. STRACH MC, Prasanna T, Carrigy MA, Bilton K, et al
    Impact of a novel breast cancer survivorship program on patient-centered outcomes: A single institutional study.
    Breast J. 2020 Mar 2. doi: 10.1111/tbj.13790.
    PubMed     Text format    
    
    

    
    Cancer Cell

28. ZHENG ZY, Anurag M, Lei JT, Cao J, et al
    Neurofibromin Is an Estrogen Receptor-alpha Transcriptional Co-repressor in Breast Cancer.
    Cancer Cell. 2020 Feb 25. pii: S1535-6108(20)30092.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

29. LE MARCHAND L, Wilkens LR, Castelfranco AM, Monroe KR, et al
    Circulating Biomarker Score for Visceral Fat and Risks of Incident Colorectal and Postmenopausal Breast Cancer: The Multiethnic Cohort Adiposity Phenotype Study.
    Cancer Epidemiol Biomarkers Prev. 2020 Mar 4. pii: 1055-9965.EPI-19-1469.
    PubMed     Text format     Abstract available
    
    
30. TANGKA FKL, Subramanian S, Jones M, Edwards P, et al
    Insurance Coverage, Employment Status, and Financial Well-Being of Young Women Diagnosed with Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2020;29:616-624.
    PubMed     Text format     Abstract available
    
    
31. SAMAYOA C, Santoyo-Olsson J, Escalera C, Stewart AL, et al
    Participant-Centered Strategies for Overcoming Barriers to Biospecimen Collection among Spanish-Speaking Latina Breast Cancer Survivors.
    Cancer Epidemiol Biomarkers Prev. 2020;29:606-615.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

32. HASKINS CB, Neuner JM, McDowell BD, Carnahan RM, et al
    Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
    Clin Breast Cancer. 2019 Sep 30. pii: S1526-8209(19)30685.
    PubMed     Text format     Abstract available
    
    
33. BARROSO-SOUSA R, Krop IE, Trippa L, Tan-Wasielewski Z, et al
    A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
    Clin Breast Cancer. 2020 Jan 30. pii: S1526-8209(20)30028.
    PubMed     Text format     Abstract available
    
    
34. XU M, Yuan Y, Yan P, Jiang J, et al
    Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2020 Jan 18. pii: S1526-8209(20)30018.
    PubMed     Text format     Abstract available
    
    
35. MAHTANI R, Holmes FA, Badve S, Caldera H, et al
    A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
    Clin Breast Cancer. 2019 Aug 21. pii: S1526-8209(19)30640.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

36. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

37. KHALAYLEH H, Khalayleh M, Diment J, Allweis TM, et al
    Breast density does not affect breast cancer tumor size assessment: A comparison of radiologic versus pathologic measurement by different imaging modalities across breast densities.
    Eur J Surg Oncol. 2020 Feb 22. pii: S0748-7983(20)30132.
    PubMed     Text format     Abstract available
    
    
38. LAI HW, Mok CW, Chang YT, Chen DR, et al
    Endoscopic assisted breast conserving surgery for breast cancer: Clinical outcome, learning curve, and patient reported aesthetic results from preliminary 100 procedures.
    Eur J Surg Oncol. 2020 Feb 20. pii: S0748-7983(20)30122.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

39. ROBINSON T, Martin RM, Yarmolinsky J
    Mendelian Randomization Analysis of Circulating Adipokines and C-reactive Protein on Breast Cancer Risk.
    Int J Cancer. 2020 Mar 5. doi: 10.1002/ijc.32947.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

40. XIONG H, Shen J, Chen Z, Yang J, et al
    H19/let7/Lin28 ceRNA network mediates autophagy inhibiting epithelialmesenchymal transition in breast cancer.
    Int J Oncol. 2020;56:794-806.
    PubMed     Text format     Abstract available
    
    
41. ZHANG F, Ma Y, Xu L, Xu H, et al
    Long noncoding RNA profile revealed by microarray indicates that lncCUEDC1 serves a negative regulatory role in breast cancer stem cells.
    Int J Oncol. 2020;56:807-820.
    PubMed     Text format     Abstract available
    
    

    
    J Biol Chem

42. GECK RC, Foley JR, Murray Stewart T, Asara JM, et al
    Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy.
    J Biol Chem. 2020 Mar 5. pii: RA119.012376. doi: 10.1074/jbc.RA119.012376.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Invest

43. GAGLIANO T, Shah K, Gargani S, Lao L, et al
    PIK3Cdelta expression by fibroblasts promotes triple-negative breast cancer progression.
    J Clin Invest. 2020 Mar 3. pii: 128313. doi: 10.1172/JCI128313.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

44. GANZ PA, Van Dyk K
    Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
    J Clin Oncol. 2020 Mar 6:JCO2000336. doi: 10.1200/JCO.20.00336.
    PubMed     Text format    
    
    
45. YADAV S, Hu C, Hart SN, Boddicker N, et al
    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    J Clin Oncol. 2020 Mar 3:JCO1902190. doi: 10.1200/JCO.19.02190.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

46. REINER AS, Robson ME, Mellemkjaer L, Tischkowitz M, et al
    Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    J Natl Cancer Inst. 2020 Mar 2. pii: 5771357. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Pathol

47. HAYWARD S, Gachehiladze M, Badr N, Andrijes R, et al
    The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer.
    J Pathol. 2020 Mar 4. doi: 10.1002/path.5415.
    PubMed     Text format     Abstract available
    
    
48. GONZALEZ-ERICSSON PI, Stovgaard ES, Sua LF, Reisenbichler E, et al
    The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.
    J Pathol. 2020 Mar 4. doi: 10.1002/path.5406.
    PubMed     Text format     Abstract available
    
    

    
    Lancet

49. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.
    PubMed     Text format    
    
    
50. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.
    PubMed     Text format    
    
    

    
    Lancet Oncol

51. GAO JJ, Cheng J, Beaver JA, Prowell TM, et al
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply.
    Lancet Oncol. 2020;21:e131.
    PubMed     Text format    
    
    
52. PALA L, Conforti F, Goldhirsch A
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
    Lancet Oncol. 2020;21:e130.
    PubMed     Text format    
    
    
53. COLEMAN R, Zhou Y, Chan A
    Adjuvant denosumab in early breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e125.
    PubMed     Text format    
    
    
54. FUSCO V, Campisi G, Bedogni A
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e124.
    PubMed     Text format    
    
    
55. DE BOISSIEU P, Trenque T
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e123.
    PubMed     Text format    
    
    
56. PETERS N, Conroy M, O'Reilly S
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e121.
    PubMed     Text format    
    
    
57. SCIMECA M, Bonfiglio R, Urbano N, Schillaci O, et al
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e122.
    PubMed     Text format    
    
    

    
    Nat Rev Clin Oncol

58. BYRNE A, Savas P, Sant S, Li R, et al
    Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
    Nat Rev Clin Oncol. 2020 Feb 28. pii: 10.1038/s41571-020-0333.
    PubMed     Text format     Abstract available
    
    

    
    NPJ Breast Cancer

59. GOODWIN PJ, Segal RJ, Vallis M, Ligibel JA, et al
    The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.
    NPJ Breast Cancer. 2020;6:6.
    PubMed     Text format     Abstract available
    
    
60. JENSEN MB, Laenkholm AV, Balslev E, Buckingham W, et al
    The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
    NPJ Breast Cancer. 2020;6:7.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

61. MU Q, Yu J, Griffin JI, Wu Y, et al
    Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
    PLoS One. 2020;15:e0228557.
    PubMed     Text format     Abstract available
    
    
62. LI M, Han M, Chen Z, Tang Y, et al
    Does marital status correlate with the female breast cancer risk? A systematic review and meta-analysis of observational studies.
    PLoS One. 2020;15:e0229899.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

63. KESAVAN R, Fromel T, Zukunft S, Laban H, et al
    Cyp2c44 regulates prostaglandin synthesis, lymphangiogenesis, and metastasis in a mouse model of breast cancer.
    Proc Natl Acad Sci U S A. 2020 Mar 2. pii: 1921381117.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

64. KIM WH, Kim HJ, Park CS, Lee J, et al
    Axillary Nodal Burden Assessed with Pretreatment Breast MRI Is Associated with Failed Sentinel Lymph Node Identification after Neoadjuvant Chemotherapy for Breast Cancer.
    Radiology. 2020 Mar 3:191639. doi: 10.1148/radiol.2020191639.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: